Skip to main content

Advertisement

SpringerLink
Log in

A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

This phase 1/2 study evaluated the safety and pharmacokinetics (part 1) and efficacy and safety (part 2) of bosutinib in Japanese Philadelphia chromosome-positive (Ph+) chronic-phase (CP) or advanced-phase chronic myeloid leukemia (CML) patients resistant/intolerant to previous imatinib (2L) or imatinib+dasatinib/nilotinib (3L). Based on dose-limiting toxicities and previous studies, the part 2 bosutinib starting dose was 500 mg/day (n = 63). For CP CML 2L (n = 28), the cumulative major cytogenetic response (MCyR) rate by week 24 was 36 % (primary endpoint); the cumulative major molecular response (MMR) rate through the study was 43 %. Transformation to accelerated/blast phase (AP/BP) was observed in one patient. Progression-free survival (PFS) and overall survival (OS) rates at 96 weeks were 94 and 96 %, respectively. Of seven advanced-phase 2L patients, one had confirmed complete hematologic response at week 84, and one had AP/BP transformation. PFS and OS rates at week 96 were 21 and 43 %. For 3L (n = 11), cumulative MCyR rate by week 24 was 18 %; cumulative MMR rate was 18 %; no transformations occurred. Common non-hematologic adverse events (AEs) were diarrhea (95 %), rash (57 %), and nasopharyngitis (51 %). Sixteen patients discontinued due to adverse events; no deaths occurred within 30 days of the last dose. Bosutinib 500 mg/day demonstrated efficacy and manageable toxicity in Japanese Ph+ CML patients resistant/intolerant to imatinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567–76.

    Article  CAS  PubMed  Google Scholar 

  2. Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486–92.

    Article  CAS  PubMed  Google Scholar 

  3. Gambacorti-Passerini C, Cortes J, Khoury H, Baccarani M, Kantarjian H, Chandy M, et al. Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: update from study SKI-200. J Clin Oncol. 2010;28:6509.

    Article  Google Scholar 

  4. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119:3403–12.

    Article  CAS  PubMed  Google Scholar 

  5. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, et al. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res. 2012;18:1092–100.

    Article  CAS  PubMed  Google Scholar 

  6. Gambacorti-Passerini C, Cortes JE, Khoury HJ, Baccarani M, Kantarjian H, Chandy M, et al. Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: update from study SKI-200. J Clin Oncol. 2010;28:6509.

    Article  Google Scholar 

  7. Sakamaki H, Ishizawa K, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, et al. Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol. 2009;89:332–41.

    Article  CAS  PubMed  Google Scholar 

  8. Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, et al. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Int J Hematol. 2009;89:679–88.

    Article  CAS  PubMed  Google Scholar 

  9. Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, et al. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. Int J Hematol. 2012;95:409–19.

    Article  CAS  PubMed  Google Scholar 

  10. Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, et al. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93:624–32

    Article  CAS  PubMed  Google Scholar 

  11. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66:11314–22.

    Article  CAS  PubMed  Google Scholar 

  12. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66:473–81.

    Article  CAS  PubMed  Google Scholar 

  13. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006;69:1527–33.

    Article  CAS  PubMed  Google Scholar 

  14. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816 V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107:752–9.

    Article  CAS  PubMed  Google Scholar 

  15. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23:477–85.

    Article  CAS  PubMed  Google Scholar 

  16. Irvine E, Williams C. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Pharmacotherapy. 2013;33:868–81.

    Article  CAS  PubMed  Google Scholar 

  17. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804:445–53.

    Article  CAS  PubMed  Google Scholar 

  18. Cervantes F, Hernandez-Boluda JC, Steegmann JL, Conde E, Alvarez-Larran A, Lopez-Jimenez J, et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica. 2003;88:1117–22.

    CAS  PubMed  Google Scholar 

  19. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143–50.

    Article  CAS  PubMed  Google Scholar 

  20. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540–6.

    Article  CAS  PubMed  Google Scholar 

  21. SPRYCEL® dasatinib Princeton. NJ: Bristol-Myers Squibb; 2014.

  22. BOSULIF® bosutinib New York. NY: Pfizer Labs; 2013.

  23. Tasigna® nilotinib East Hanover. NJ: Novartis Pharmaceuticals Corporation; 2014.

Download references

Acknowledgments

Editorial and medical writing support was provided by Simon J. Slater, PhD, of Complete Healthcare Communications, Inc., and was funded by Pfizer Inc. This study was sponsored by Wyeth Research, which was acquired by Pfizer Inc in October 2009.

Conflict of interest

Dr. Nakaseko reports Grants and scholarship support from Pfizer Inc. Dr. Takahashi reports Grants, personal fees and non-financial support from Pfizer Inc during the conduct of the study; Grants and personal fees from Novartis, Bristol-Myers Squibb, Kyowa Hakko Kirin, Chugai Pharma, Dainippon Sumitomo Pharma, Celgene, Janssen Pharma; Grants from Takeda Pharma; and personal fees from Asahikasei Pharma outside the submitted work. Dr. Kobayashi reports Grants from Pfizer Inc during the conduct of the study; Grants from ARIAD Pharmaceuticals, Inc., Boehringer Ingelheim, Novartis Pharma K·K., Otsuka Pharmaceuticals Co., Ltd., and Onconova Therapeutics, Inc., outside the submitted work. Dr. Yamamoto reports Grants and non-financial support from Pfizer Inc during the conduct of the study; Grants and non-financial support from Novartis Pharma K·K and Grants from ARIAD Pharmaceuticals, Inc, outside the submitted work. Dr. Kawaguchi reports Grants from Pfizer Inc during the conduct of the study. Dr. Ishizawa reports personal fees from Chugai Pharma, Takeda Pharma, Celgene, Janssen Pharma, and Sanofi, outside the submitted work. Dr. Taniwaki reports Grants from Pfizer Inc during the conduct of the study; Grants and/or personal fees from Bristol-Myers Squibb, Novartis, Kyowa Hakko Kirin, Chugai Pharma, Dainippon Sumitomo Pharma, Celgene, Janssen Pharma, Takeda Pharma, and Asahikasei Pharma, outside the submitted work. Drs. Ono, Fujii, and Shibata are employees of Pfizer Japan and contributed to this clinical trial as follows: protocol development (pharmacokinetics components) and data analysis (Dr. Ono; clinical pharmacologist); protocol development (statistical components) and data analysis (Dr. Fujii; study statistician); protocol development (clinical components), trial management, and data analysis (Dr. Shibata; study clinician). Drs. Ohashi, Nakagawa, Ohnishi, Miyamura, and Okada have nothing to disclose.

Author information

Authors and Affiliations

  1. Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan

    Chiaki Nakaseko

  2. Department of Hematology, Nephrology, and Rheumatology, Akita University School of Medicine, Akita, Japan

    Naoto Takahashi

  3. Department of Rheumatology and Hematology, Tohoku University Hospital, Miyagi, Japan

    Kenichi Ishizawa

  4. Department of Hematology and Oncology, National Cancer Center Hospital, Tokyo, Japan

    Yukio Kobayashi

  5. Hematology Department, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan

    Kazuteru Ohashi

  6. Department of Chemotherapy, Japanese Red Cross Medical Center, Tokyo, Japan

    Yasunori Nakagawa

  7. Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Aichi, Japan

    Kazuhito Yamamoto

  8. Hematology Division, Japanese Red Cross Nagoya First Hospital, Aichi, Japan

    Koichi Miyamura

  9. Department of Hematology and Oncology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto City, Japan

    Masafumi Taniwaki

  10. Division of Hematology, The Hospital of Hyogo College of Medicine, Hyogo, Japan

    Masaya Okada

  11. Department of Hematology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan

    Tatsuya Kawaguchi

  12. Oncology Clinical Research, Pfizer Japan, Tokyo, Japan

    Atsushi Shibata

  13. Clinical Statistics, Pfizer Japan, Tokyo, Japan

    Yosuke Fujii

  14. Clinical Pharmacology, Pfizer Japan, Tokyo, Japan

    Chiho Ono

  15. Oncology Center, Hamamatsu University School of Medicine, Shizuoka, Japan

    Kazunori Ohnishi

Authors
  1. Chiaki Nakaseko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoto Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenichi Ishizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yukio Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuteru Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasunori Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuhito Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Koichi Miyamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masafumi Taniwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masaya Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tatsuya Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Atsushi Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yosuke Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Chiho Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kazunori Ohnishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chiaki Nakaseko.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakaseko, C., Takahashi, N., Ishizawa, K. et al. A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. Int J Hematol 101, 154–164 (2015). https://doi.org/10.1007/s12185-014-1722-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-014-1722-8

Keywords

Search

Navigation